Jafron Biomedical Co.,Ltd. (300529.SZ)
CNY 30.04
(-0.07%)
CNY 30.04
(-0.07%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.53 Billion CNY | -25.01% |
| 2022 | 2.05 Billion CNY | -9.77% |
| 2021 | 2.27 Billion CNY | 36.72% |
| 2020 | 1.66 Billion CNY | 34.7% |
| 2019 | 1.23 Billion CNY | 43.19% |
| 2018 | 862.06 Million CNY | 42.59% |
| 2017 | 604.56 Million CNY | 32.49% |
| 2016 | 456.29 Million CNY | 6.05% |
| 2015 | 430.28 Million CNY | 36.92% |
| 2014 | 314.25 Million CNY | 23.67% |
| 2013 | 254.1 Million CNY | 22.9% |
| 2012 | 206.75 Million CNY | 28.84% |
| 2011 | 160.47 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 574.01 Million CNY | 68.96% |
| 2024 Q3 | 580.83 Million CNY | -1.29% |
| 2024 Q2 | 588.43 Million CNY | 2.51% |
| 2023 FY | 1.53 Billion CNY | -25.01% |
| 2023 Q4 | 339.73 Million CNY | -11.38% |
| 2023 Q3 | 383.34 Million CNY | 8.04% |
| 2023 Q1 | 460.44 Million CNY | 26.42% |
| 2023 Q2 | 354.83 Million CNY | -22.94% |
| 2022 Q3 | 384.7 Million CNY | -46.05% |
| 2022 FY | 2.05 Billion CNY | -9.77% |
| 2022 Q2 | 713.1 Million CNY | 21.01% |
| 2022 Q1 | 589.29 Million CNY | -22.43% |
| 2022 Q4 | 364.23 Million CNY | -5.32% |
| 2021 FY | 2.27 Billion CNY | 36.72% |
| 2021 Q1 | 493.38 Million CNY | -7.46% |
| 2021 Q4 | 759.72 Million CNY | 51.81% |
| 2021 Q3 | 500.43 Million CNY | -3.74% |
| 2021 Q2 | 519.85 Million CNY | 5.37% |
| 2020 Q4 | 533.17 Million CNY | 38.41% |
| 2020 Q3 | 385.2 Million CNY | -8.2% |
| 2020 FY | 1.66 Billion CNY | 34.7% |
| 2020 Q1 | 324.83 Million CNY | -18.67% |
| 2020 Q2 | 419.6 Million CNY | 29.17% |
| 2019 Q1 | 251.84 Million CNY | -6.75% |
| 2019 Q2 | 312.47 Million CNY | 24.08% |
| 2019 Q4 | 399.39 Million CNY | 47.54% |
| 2019 FY | 1.23 Billion CNY | 43.19% |
| 2019 Q3 | 270.71 Million CNY | -13.37% |
| 2018 Q4 | 270.06 Million CNY | 30.66% |
| 2018 Q2 | 210.44 Million CNY | 20.36% |
| 2018 Q1 | 174.85 Million CNY | -8.99% |
| 2018 FY | 862.06 Million CNY | 42.59% |
| 2018 Q3 | 206.69 Million CNY | -1.78% |
| 2017 Q4 | 192.11 Million CNY | 40.26% |
| 2017 Q1 | 122.39 Million CNY | -13.62% |
| 2017 FY | 604.56 Million CNY | 32.49% |
| 2017 Q2 | 153.07 Million CNY | 25.07% |
| 2017 Q3 | 136.97 Million CNY | -10.52% |
| 2016 Q2 | 113.88 Million CNY | 8.13% |
| 2016 FY | 456.29 Million CNY | 6.05% |
| 2016 Q4 | 141.69 Million CNY | 48.51% |
| 2016 Q3 | 95.4 Million CNY | -16.22% |
| 2016 Q1 | 105.32 Million CNY | -24.08% |
| 2015 FY | 430.28 Million CNY | 36.92% |
| 2015 Q4 | 138.72 Million CNY | 34.13% |
| 2015 Q3 | 103.43 Million CNY | 2.13% |
| 2015 Q2 | 101.26 Million CNY | 16.6% |
| 2015 Q1 | 86.85 Million CNY | 0.0% |
| 2014 FY | 314.25 Million CNY | 23.67% |
| 2013 FY | 254.1 Million CNY | 22.9% |
| 2012 FY | 206.75 Million CNY | 28.84% |
| 2011 FY | 160.47 Million CNY | 0.0% |